Zoetis Inc. Class A (ZTS)
NYSE: ZTSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ZTS stock chart
Technical analysisKey statistics
All statistics- Market cap
- $32.14B
- P/E (TTM)
- 13.45
- Forward P/E
- 12.41
- EPS (TTM)
- $5.88
- Dividend yield
- 2.64% ($2.09)
- Ex-dividend date
- Oct 30, 2026
- 52-week range
- 68.77 – 132.49
- Day range
- 78.80 – 83.08
- Volume / Avg
- 6.10M / 4.51M
- Beta
- —
- Shares outstanding
- 406.32M
52-week range
ZTS stock today
On Nov 20, ZTS ended the session at $79.11, shedding $1.68 (2.08%), versus the S&P 500's 3.70% decline. Shares are 40.3% below their 52-week high of $132.49, set on Feb 12, 2026 and 15.0% above the 52-week low of $68.77, near the bottom of the past year's range. ZTS is down 37.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 35.2%.
At 13.5x trailing earnings, Zoetis trades below the peer-group median of 43.2x. Its forward P/E of 12.4x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. Zoetis pays an annual dividend of $2.09 per share, a 2.64% yield at the current price.
Summary generated from market data by MetaCap's automated system. Methodology
About Zoetis
Company profileZoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Ms. Kristin C. Peck
- Headquarters
- Parsippany, NJ
- Employees
- 14,500
- IPO year
- 2013
- Website
- zoetis.com
Financial highlights
Full financialsIn fiscal 2025, Zoetis generated $9.47 billion in revenue, up 2.3% from fiscal 2024, its 10th consecutive year of revenue growth. Net income was $2.67 billion (+7.5% year over year), for a net margin of 28.2% versus a median of 26.2% in the prior 5 years. Gross margin was 71.8% (up from 70.6%).
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $9.47B | $9.26B | $8.54B | $8.08B | $7.78B |
| Growth | +2.28% | +8.33% | +5.74% | +3.91% | +16.49% |
| Net income | $2.67B | $2.49B | $2.34B | $2.11B | $2.04B |
| EPS (diluted) | $6.02 | $5.47 | $5.07 | $4.49 | $4.27 |
Analyst forecast
ForecastConsensus (16 analysts)
buy
Avg. price target
$89.69+13.37%
- Strong buy 4
- Buy 2
- Hold 10
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $1.44 vs $1.51
- Surprise
- -4.64%
Dividends
Dividend history- Annual dividend
- $2.09
- Dividend yield
- 2.64%
- Last payment
- $0.53
- Ex-dividend date
- Oct 30, 2026
ZTS news
All ZTS news- Zoetis Inc. (ZTS) Presents at Jefferies Global Healthcare Conference 2026 TranscriptSeeking Alpha
- Zoetis' Cytopoint Plus Gets USDA License for 75-Day Canine Itch ReliefNasdaqZTS, ADPT, ACIU, AMRX
- ZTS Q3 Earnings Call Highlights Competitive Pressures and OutlookNasdaq
- What Zoetis (ZTS) Said on Its Q3 Earnings CallNasdaq
- Zoetis Takes Over #296 Spot From ResMedNasdaqZTS, RMD
- Zoetis: Quality Company Trading CheapSeeking Alpha
- Zoetis narrows 2026 revenue outlook to $9.22B-$9.32B while raising adjusted EPS to $6.25-$6.35Seeking Alpha
- Zoetis Inc. (ZTS) Q3 2026 Earnings Call TranscriptSeeking Alpha
Zoetis peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| GMABGenmab A/S ADS | 50.60 | -1.46% | $31.20B | vs ZTS |
| INSMInsmed Incorporated | 141.33 | -2.17% | $31.01B | vs ZTS |
| ROIVRoivant Sciences Ltd. | 38.66 | -0.78% | $28.01B | vs ZTS |
| RPRXRoyalty Pharma plc Class A | 68.45 | +1.08% | $39.36B | vs ZTS |
| UTHRUnited Therapeutics Corporation | 554.73 | -0.78% | $23.63B | vs ZTS |
| VTRSViatris Inc. | 19.63 | -1.26% | $22.50B | vs ZTS |
| ONCBeOne Medicines Ltd. ADR | 390.94 | -2.19% | $44.66B | vs ZTS |
| ALNYAlnylam Pharmaceuticals Inc. | 143.82 | -2.71% | $19.26B | vs ZTS |
Indexes, lists and sector
Zoetis stock FAQ
What is Zoetis's stock price today?
ZTS last traded at $79.11 as of Nov 20, 4:00 PM EST, down 2.08% on the day. Prices are delayed at least 15 minutes.
Does Zoetis pay a dividend?
Yes. Zoetis pays $2.09 per share annually, a 2.64% yield. The most recent dividend of $0.53 had an ex-dividend date of Oct 30, 2026.
What is ZTS's P/E ratio?
ZTS trades at a trailing P/E ratio of 13.45 and a forward P/E of 12.41, compared with a median of 43.2 for its closest peers.
Is Zoetis in the S&P 500?
Yes. Zoetis (ZTS) is a constituent of the S&P 500 index.
Who is Zoetis's CEO?
Ms. Kristin C. Peck is the chief executive officer of Zoetis Inc. Class A, which has about 14,500 employees.
What is the ZTS 52-week high?
The 52-week high for ZTS is $132.49 and the 52-week low is $68.77. The stock is currently 40.3% below its high.